Literature DB >> 10737910

Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil.

H Matsushima1, T Watanabe, S Higuchi.   

Abstract

The pharmacokinetics of tamsulosin (TAM) was investigated using male Sprague-Dawley rats in which plasma alpha(1)-acid glycoprotein (alpha(1)-AGP) levels were elevated by the subcutaneous injection of 0.2 mL/kg of turpentine oil. alpha(1)-AGP levels increased about eight times after turpentine oil treatment, causing a threefold decrease in plasma unbound fraction (f(u)) of TAM. When 0.3 mg/kg of TAM was dosed intravenously, total and nonrenal clearances (CL(tot) and CL(nr)) in turpentine-treated rats were 47% and 44% lower than those in nontreated controls, respectively. The area under the concentration-time curve of plasma unbound TAM (AUC(inf,u)) was lower than that in the control. When 1 mg/kg of TAM was dosed orally, oral clearance (CL(oral)) in alpha1-AGP-induced rats was 65% lower than in the control. The AUC(inf,u) and unbound oral clearance (CL(oral,u)) were nearly equal in both groups. Moreover, a positive correlation was observed between fu and CL(oral) of TAM (r(2) = 0.603, P < 0.01), whereas no correlation was observed between f(u) and CL(oral,u). The absolute bioavailability (BA) increased from 19.2% to 46.9% by induction of alpha(1)-AGP. These results suggest that decreased f(u) caused by the elevation of plasma alpha(1)-AGP level affects the pharmacokinetics of TAM, but does not affect the CL(oral,u,) which represents the hepatic metabolism of TAM. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737910     DOI: 10.1002/(SICI)1520-6017(200004)89:4<490::AID-JPS6>3.0.CO;2-O

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

Review 1.  Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.

Authors:  Gabriela Franco-Salinas; Jean J M C H de la Rosette; Martin C Michel
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

2.  Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels.

Authors:  N Jauregizar; R Calvo; E Suarez; A Quintana; E Raczka; J C Lukas
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant.

Authors:  Kazuhiko Hanada
Journal:  Drugs R D       Date:  2017-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.